How our Bodies Sabotage Cancer Treatments

Scientist examining samples under a microscope in a laboratory

Your immune system may be sabotaging your cancer treatment from the inside — and scientists just found the switch responsible.

Quick Take

A protein called SLAMF6 acts like a built-in brake on your immune cells, quietly weakening their ability to fight cancer.
New research shows that blocking SLAMF6 with an antibody can recharge exhausted immune cells and shrink tumors in lab models.
The findings could explain why many patients stop responding to checkpoint immunotherapy drugs over time.
All current evidence comes from animal and lab studies — no human clinical trial results exist yet.

Why Immunotherapy Stops Working for So Many Patients

Immunotherapy changed cancer treatment. Drugs that block immune checkpoints — proteins that tell your immune cells to stand down — have saved lives that older treatments could not. But here is the problem doctors keep running into: many patients respond well at first, then the cancer comes roaring back. The tumors find a way around the treatment. Researchers have long suspected another hidden brake was at work inside the immune cells themselves. They may have just found it.

The protein is called SLAMF6. It sits on the surface of a specific type of immune cell called a CD8+ T cell — the kind that hunts and kills cancer cells. New research published in Nature in early 2026 found that SLAMF6 does not need a signal from the tumor to cause problems. ^[3] It locks onto itself on the T cell’s own surface, triggering an internal signal that slows the cell down. Think of it as a soldier who keeps tripping over his own bootlaces before he even reaches the enemy.

What SLAMF6 Actually Does to Your Immune Cells

When SLAMF6 is active, it weakens T cells in two important ways. It reduces how hard they fight, and it cuts down the production of what researchers call stem-like T cells — the durable, long-lasting immune fighters that can keep attacking a tumor for months or years. ^[1] Lose those stem-like cells, and your immune response runs out of fuel. The 2026 Nature study found that SLAMF6 is concentrated on exactly this type of long-lived T cell, which is why its effects on treatment durability could be so significant. ^[3]

Earlier research backed this up. A study published in eLife found that T cells lacking SLAMF6 were stronger fighters. They killed melanoma cells more effectively and produced longer-lasting tumor remission in animal models. ^[2] The researchers called SLAMF6 a “constitutive inhibitory immune receptor” — meaning it is always switched on, always holding the immune system back, regardless of what the tumor is doing. ^[2] That is a key distinction from other checkpoint proteins, which are triggered by signals from outside the cell.

The Brake Works Even in Blood Cancer

The SLAMF6 story is not limited to solid tumors. A study published in Nature Cancer found that leukemia cells — specifically acute myeloid leukemia (AML) cells — exploit SLAMF6 to hide from T cells. ^[5] When researchers knocked out SLAMF6 in those leukemia cells, T cells immediately became more active and started killing them. A fully human antibody designed to block SLAMF6’s binding interface then showed strong T cell-driven killing of AML cells in both lab and humanized animal models. ^[5] Research from MD Anderson Cancer Center also found that anti-SLAMF6 treatment corrected CD8+ T cell dysfunction and reduced leukemic tumor burden. ^[4]

These results, taken together, build a consistent picture. SLAMF6 is not a quirk of one cancer type. It appears to be a broad immune suppressor that different cancers benefit from — whether they express SLAMF6 themselves or simply benefit from what it does to the T cells trying to attack them.

Why This Is Not a Done Deal

Here is where honest science requires a pause. Every result described above came from mice, cell cultures, or humanized animal models. No completed human clinical trial has tested whether blocking SLAMF6 actually extends survival in cancer patients. ^[2]^[3]^[5] The Nature abstract itself notes that the role of SLAMF6 “remains ambiguous” because it can have both activating and inhibitory effects depending on context. ^[3] That is not a minor footnote — it means the biology is still being worked out. The AML study also found no clear link between SLAMF6 levels and patient survival in existing datasets. ^[5]

There is also no published safety data. Blocking an immune regulator can cause the immune system to attack healthy tissue. That risk is real and well-documented with existing checkpoint drugs. Until phase 1 human trials produce adverse-event data, the therapeutic upside is only half the story. The science here is genuinely exciting — the mechanistic case is strong and the animal results are consistent across multiple research groups and cancer types. But the jump from a promising lab finding to a drug that helps patients is long, and many promising targets have not survived that journey.

What Comes Next and Why It Matters

The next critical step is a first-in-human clinical trial testing a SLAMF6-blocking antibody, measuring both immune response and patient outcomes like progression-free survival. Researchers also need to identify which patients are most likely to benefit — particularly those who have already stopped responding to existing checkpoint drugs like PD-1 or PD-L1 blockers. ^[1] If SLAMF6 blockade works in those patients, it could fill one of the biggest gaps in cancer immunotherapy today. That is worth watching closely — but with clear eyes about how far the evidence still needs to travel.